Compare SRPT & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | AVDL |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1997 | 1996 |
| Metric | SRPT | AVDL |
|---|---|---|
| Price | $23.85 | $21.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 9 |
| Target Price | ★ $26.23 | $18.38 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 02-25-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,413,715,000.00 | $248,517,000.00 |
| Revenue This Year | $13.72 | $65.47 |
| Revenue Next Year | N/A | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 47.15 | ★ 79.88 |
| 52 Week Low | $10.42 | $6.38 |
| 52 Week High | $128.75 | $23.57 |
| Indicator | SRPT | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 58.29 |
| Support Level | $20.86 | $21.40 |
| Resistance Level | $24.12 | $21.53 |
| Average True Range (ATR) | 0.95 | 0.11 |
| MACD | 0.16 | -0.07 |
| Stochastic Oscillator | 92.22 | 46.67 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.